Abstracts tagged "Biomarkers"

Abstract Number: 392 • 2014 ACR/ARHP Annual Meeting
Neuroendocrine Hormone and Metabolic Peptide Levels in the Earliest Phases of Rheumatoid Arthritis – Do Free Fatty Acids Play a Role?
Man Wai Tang¹, Frieda A. Koopman², Jan P.M. Visscher², Marjolein J.H. de Hair², Danielle M. Gerlag^2,3 and Paul P. Tak^2,4, ¹Division of Clinical Immunology and Rheumatology & Department of Experimental Immunology, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, ²Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ³GlaxoSmithKline, Cambridge, United Kingdom, ⁴University of Cambridge, Cambridge and GlaxoSmithKline, Stevenage, United Kingdom
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease associated with several neuroendocrine hormones and metabolic peptides. The crosstalk between the hormones and the immune…
Abstract Number: 2928 • 2014 ACR/ARHP Annual Meeting
Serum IL-33 Level Is Increased in Rheumatoid Arthritis and Predicts Response to Rituximab in Combination with High Serum IgG Level and Autoantibody Positivity: An Open-Label, Prospective, Multicentre Biological Trial
Jérémie Sellam¹, Houria Chavez², Stéphanie Rouanet³, Nathalie Vernet³, Bineta Ly⁴, Sandrine Marion-Thore⁵, Bernard Combe⁶, Jean Sibilia⁷, Jacques Tebib⁸, Gilles Chiocchia⁹, Maxime Dougados¹⁰, Yassine Taoufik² and Xavier Mariette¹¹, ¹AP-HP, Saint-Antoine Hospital, Rheumatology Department and DHU i2B, Paris, France, ²Biologic Immunology, Hopital Bicetre, Université Paris Sud, AP-HP, Kremlin Bicetre, France, ³Biostatistics, Roche France, Boulogne-Billancourt, France, ⁴INSERM U1012, Universite Paris-Sud, Kremlin Bicetre, France, ⁵INSERM U1016, Université Versailles Saint-Quentin, Montigny le Bretonneux, France, ⁶Immuno-Rhumatologie, Hôpital Lapeyronie, Montpellier, France, ⁷Division of Rheumatology, University Hospital of Strasbourg, Strasbourg, France, ⁸Rheumatology, University Hospital Lyon, Lyon, France, ⁹Université Versailles-Saint Quentin, Montigny le Bretonneux, France, ¹⁰INSERM (U1153): Clinical Epidemiology and Biostatistics, PRES Sorbonne Paris-Cité, Paris, France., Paris, France, ¹¹rheumatology, Université Paris-Sud, Le Kremlin Bicêtre, France
Background/Purpose . The recent discovered cytokine interleukin-33 (IL33) could be involved in B-cell activation as well as in RA pathophysiology. After a whole-blood transcriptomic analysis…
Abstract Number: 1902 • 2014 ACR/ARHP Annual Meeting
Utility of Glyca, a Novel Inflammatory Marker, for Assessment of Rheumatoid Arthritis Disease Activity
Michelle Ormseth¹, Cecilia P. Chung², Joseph F. Solus³, Annette M. Oeser³, Margery A. Connelly⁴, Jim Otvos⁴ and C Michael Stein³, ¹Department of Medicine, Division of Rheumatology, Vanderbilt University, Nashville, TN, ²Medicine, Vanderbilt University, Nashville, TN, ³Vanderbilt University, Nashville, TN, ⁴LipoScience, Inc., Raleigh, NC
Background/Purpose GlycA is a novel inflammatory biomarker measured from the nuclear magnetic resonance (NMR) spectra obtained for lipoprotein particle analysis. It represents a distinct peak…
Abstract Number: 1408 • 2014 ACR/ARHP Annual Meeting
Inflammatory Biomarkers, Sleep Quantity and Sleep Quality in Rheumatoid Arthritis
Alexander Fine¹, Michelle A. Frits², Jing Cui³, Christine K. Iannaccone⁴, Jonathan S. Coblyn⁵, Michael E. Weinblatt⁶, Nancy A. Shadick⁷ and Yvonne C. Lee⁴, ¹Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Division of Rheumatology, Brigham and Women's Hospital, Boston, MA, ³Rheumatology, Brigham and Womens Hospital, Boston, MA, ⁴Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁵Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁶Division of Rheumatology & Immunology, Brigham and Women's Hospital, Boston, MA, ⁷Brigham and Women's Hospital/Harvard University, Cambridge, MA
Background/Purpose: Sleep problems affect over 60% of rheumatoid arthritis (RA) patients. However, little is known about the association between sleep problems and inflammatory pathways in…
Abstract Number: 808 • 2014 ACR/ARHP Annual Meeting
Biomarkers of Disease Activity in Vasculitis
Alicia Rodriguez-Pla¹, Roscoe L. Warner², David Cuthbertson³, Simon Carette⁴, Gary S. Hoffman⁵, Nader A. Khalidi⁶, Curry L Koening⁷, Carol A. Langford⁸, Kathleen Maksimowicz-McKinnon⁹, Larry W. Moreland¹⁰, Christian Pagnoux⁴, Philip Seo¹¹, Ulrich Specks^12,13, Kenneth J. Warrington¹⁴, Steven R. Ytterberg¹⁵, Peter A. Merkel¹⁶, Kent J. Johnson², Paul A. Monach¹⁷ and For the Vasculitis Research Consortium¹⁸, ¹Rheumatology, Boston University, Boston, MA, ²Pathology, University of Michigan, Ann Arbor, MI, ³Department of Biostatistics, University of South Florida, Tampa, FL, ⁴Division of Rheumatology, University of Toronto, Toronto, ON, Canada, ⁵Center for Vasculitis Care and Research, Cleveland Clinic Foundation, Cleveland, OH, ⁶Internal Medicine/Rheumatology, McMaster University, Hamilton, ON, Canada, ⁷Division of rheumatology, George E. Wahlen Department of Veterans Affairs Medical Center Salt Lake City and University of Utah, University of Utah School of Medicine, Salt Lake City, UT, ⁸Center for Vasculitis Care and Research, Cleveland Clinic, Cleveland, OH, ⁹Rheumatology, Henry Ford Hospital, Detroit, MI, ¹⁰Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ¹¹Rheumatology Division, Johns Hopkins Vasculitis Center, Johns Hopkins University, Baltimore, MD, ¹²Frederichs Dr NW, Mayo Clinic, Rochester, MN, ¹³Mayo Clinic, Rochester, MN, ¹⁴Division of Rheumatology, Mayo Clinic, Rochester, MN, ¹⁵Rheumatology Division, Mayo Clinic, Rochester, MN, ¹⁶University of Pennsylvania, Philadelphia, PA, ¹⁷Section of Rheumatology, Vasculitis Center, Boston University School of Medicine, Boston, MA, ¹⁸U Pennsylvania, Philadelphia, PA
Background/Purpose To identify circulating proteins that distinguish between active vasculitis and remission in giant cell arteritis (GCA), Takayasu's arteritis (TAK), polyarteritis nodosa (PAN) and eosinophilic…
Abstract Number: 368 • 2014 ACR/ARHP Annual Meeting
Serum C1M Level Predicts Disease Progression and Early Treatment Efficacy in Rheumatoid Arthritis
Anne C. Bay-Jensen¹, Anne Sofie Siebuhr², Inger Byrjalsen³, Claus Christiansen³ and Morten Asser Karsdal¹, ¹Nordic Bioscience, Biomarkers and Research, Herlev, Denmark, ²Rheumatology, Nordic Bioscience, Biomarkers and Research, Herlev, Denmark, ³Nordic Bioscience, Herlev, Denmark
Background/Purpose: Rheumatoid arthritis (RA) is partly characterized by joint destruction. Personalized health care is needed in RA to enable i) prediction of those patients that…
Abstract Number: 156 • 2013 ACR/ARHP Annual Meeting
Cartilage Peptide Profiling: Identifying Novel OA Biomarkers For Early Disease Detection
Valentina Calamia¹, Lucía Lourido¹, Diego López¹, Jesus Mateos¹, Patricia Fernández-Puente¹, Carolina Fernández-Costa², Beatriz Rocha², Cristina Ruiz-Romero³ and Francisco J. Blanco¹, ¹Osteoarticular and Aging Research Laboratory, Proteomics Unit-Associated Node to ProteoRed-ISCIII, INIBIC-CHUAC, A Coruña, Spain, ²Grupo de Proteomica-PBR2-ProteoRed/ISCIII-Servicio de Reumatologia. Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). As Xubias, 15006., A Coruña, Spain, ³Grupo de Proteomica-PBR2-ProteoRed/ISCIII Servicio de Reumatologia. Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). As Xubias, 15006 A Coruña, Spain, A Coruña, Spain
Background/Purpose: Cartilage secretome contains a complex matrix of proteolytically derived peptides that may provide useful information of the biological events occurring in the articular joint…
Abstract Number: 2391 • 2013 ACR/ARHP Annual Meeting
Pathogenic Pro-Inflammatory Cytokine Production Induced By Synovial Fluid From RA Patients Is Related To Levels Of Endogenous TLR4 Ligands and Is Blocked By a Novel Therapeutic Anti-Human TLR4 Monoclonal Antibody, NI-0101
Limin Shang¹, Greg Elson¹, Jeremy Sokolove², Iain B. McInnes³, James Reilly⁴, Eric Hatterer¹, Marie Kosco-Vilbois⁵, Walter Ferlin⁵, Emmanuel Monnet⁵ and Cristina de Min⁶, ¹NovImmune S.A., Plan-Les-Ouates, Geneva, Switzerland, ²VA Palo Alto Healthcare System and Stanford University, Palo Alto, CA, ³Glasgow Biomedical Research Centre, University of Glasgow, Glasgow, United Kingdom, ⁴University of Glasgow, Glasgow, United Kingdom, ⁵NovImmune S.A., Geneva, Switzerland, ⁶Novimmmune S.A., Plan-Les-Ouates, Geneva, Switzerland
Background/Purpose: Deregulation of Toll-Like Receptor 4 (TLR4) signaling is thought to play a role in the pathogenesis of certain autoimmune diseases. In rheumatoid arthritis (RA),…
Abstract Number: 1876 • 2013 ACR/ARHP Annual Meeting
Potential Chondrogenic Biomarkers For Cell-Based Therapy Monitoring In Osteoarthritis
Beatriz Rocha¹, Valentina Calamia², Vanessa Casas³, Lucia Lourido², Carolina Fernandez-Costa², Patricia Fernandez-Puente², Jesus Mateos², Montserrat Carrascal³, Francisco J. Blanco² and Cristina Ruiz-Romero^1,4, ¹Grupo de Proteomica-PBR2-ProteoRed/ISCIII-Servicio de Reumatologia. Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). As Xubias, 15006., A Coruña, Spain, ²Osteoarticular and Aging Research Laboratory, Proteomics Unit-Associated Node to ProteoRed-ISCIII, INIBIC-CHUAC, A Coruña, Spain, ³Laboratorio de Proteómica CSIC/UAB, Barcelona, Spain, ⁴CIBER-BBN, INIBIC-CHUAC, A Coruña, Spain
Background/Purpose: Chondrogenesis occurs as a result of mesenchymal stem cells (MSCs) condensation and chondroprogenitor cell differentiation. Following chondrogenesis, the chondrocytes remain as resting cells to…
Abstract Number: 1321 • 2013 ACR/ARHP Annual Meeting
Vasoactive Intestinal Peptide Serum Levels As a Marker Of Prognosis In Rheumatoid Arthritis
Rosario Garcia-Vicuña¹, Ana M. Ortiz², Iria Valino-Seoane³, Amalia Lamana¹, Javier Leceta³, Yasmina Juarranz³, Isidoro González-Alvaro², Rosa P Gomariz³ and Carmen Martinez-Mora⁴, ¹Rheumatology, Hospital Universitario de La Princesa. IIS Princesa, Madrid, Spain, ²Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, ³Cellular Biology, School of Biology. Universidad Complutense de Madrid, Madrid, Spain, ⁴Cellular Biology, School of Medicine. Universidad Complutense de Madrid, Madrid, Spain
Background/Purpose: The current shift to earlier treatment of Rheumatoid Arthritis (RA) has a major unmet need in the availability of biomarkers to identify patients requiring more…
Abstract Number: 381 • 2013 ACR/ARHP Annual Meeting
Coronary Endothelial Dysfunction Directly Measured By N13 Positron Emission Tomography (PET) Is Detected In Established Rheumatoid Arthritis (RA), But Not Early RA
OM Troum¹, OL Pimienta¹, B Hidalgo² and WA Hsueh³, ¹Keck School of Medicine, University of Southern California, Los Angeles, CA, ²Biostatistics, University of Alabama, Birmingham, AL, ³Medicine, Weill Cornell Medical College, Houston, TX
Background/Purpose: Rheumatoid arthritis (RA) is associated with increased risk of cardiovascular (CV) disease. The endothelium is a key regulator of vascular function. Subclinical CV disease and…
Abstract Number: 2374 • 2013 ACR/ARHP Annual Meeting
Pharmacodynamics Of a Novel Jak1 Selective Inhibitor In Rat Arthritis and Anemia Models and In Healthy Human Subjects
Jeffrey Voss¹, Candace Graff², Annette Schwartz³, Deborah Hyland⁴, Maria Argiriadi⁴, Heidi Camp⁵, Lori Dowding⁴, Michael Friedman⁴, Kristine Frank⁵, Jonathon George⁴, Eric Goedken⁴, Gloria Lo Schiavo⁴, Michael Morytko⁴, Robert o'Brien⁴, Robert Padley⁶, Matthew Rosebraugh⁵, Michael Rozema⁵, Kent Stewart⁵, Grier Wallace⁴, Neil Wishart⁴, Anwar Murtaza⁷ and Lisa Olson³, ¹Immunology, AbbVie Pharmaceuticals, Worcester, MA, ²Drug Metabolism and Pharmacokinetics, Abbvie Pharmaceuticals, worcester, MA, ³AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA, ⁴Abbvie Pharmaceuticals, worcester, MA, ⁵abbvie pharmaceuticals, north chicago, IL, ⁶AbbVie, Inc, North Chicago, IL, ⁷Broad Institute, Cambridge, MA
Background/Purpose: Anti-cytokine therapies have become the mainstay of treatment for rheumatoid arthritis (RA) disease symptoms and can arrest disease progression. Despite numerous treatment options there…
Abstract Number: 1878 • 2013 ACR/ARHP Annual Meeting
Proteomics Analysis Of Cartilage Secretome: A Powerful Tool For The Discovery Of OA Biomarkers
Lucía Lourido¹, Valentina Calamia¹, Patricia Fernández-Puente¹, Jesus Mateos¹, Beatriz Rocha², Carolina Fernández-Costa², Francisco J. Blanco¹ and Cristina Ruiz-Romero³, ¹Osteoarticular and Aging Research Laboratory, Proteomics Unit-Associated Node to ProteoRed-ISCIII, INIBIC-CHUAC, A Coruña, Spain, ²Grupo de Proteomica-PBR2-ProteoRed/ISCIII-Servicio de Reumatologia. Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). As Xubias, 15006., A Coruña, Spain, ³Grupo de Proteomica-PBR2-ProteoRed/ISCIII Servicio de Reumatologia. Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). As Xubias, 15006 A Coruña, Spain, A Coruña, Spain
Background/Purpose: Osteoarthritis (OA) is characterized by the progressive loss of cartilage structural extracellular matrix (ECM) components, mainly collagenous and non-collagenous proteins. The release of these…
Abstract Number: 1312 • 2013 ACR/ARHP Annual Meeting
A Multi-Biomarker Disease Activity Score Correlates With Radiographic Progression In Early Rheumatoid Arthritis: Results From a Randomized Trial
Karen Hambardzumyan¹, Rebecca Bolce², Scott E. Cruickshank³, Eric H. Sasso², David Chernoff², Kristina Forslind⁴, Saedis Saevarsdottir⁵, Ingemar F. Petersson⁶, Pierre Geborek⁷, Sofia Ernestam⁸ and Ronald F van Vollenhoven⁹, ¹ClinTRID, the Karolinska Institute, Stockholm, Sweden, ²Crescendo Bioscience Inc., South San Francisco, CA, ³Scott E. Cruickshank and Associates, Inc., Santa Barbara, CA, ⁴Department of Medicine, Karolinska Institute, Stockholm, Department of Medicine, Karolinska Institute,, Stockholm, Sweden, ⁵Karolinska Institutet, Stockholm, Sweden, ⁶Lund University, Lund, Sweden, ⁷Section of Rheumatology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden, ⁸Huddinge Hospital, Karolinska University Hospital, Huddinge, Sweden, ⁹ClinTRID, Department of Medicine, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: In early rheumatoid arthritis (eRA), predictors of radiographic damage would be useful for optimal targeting of therapy. It has been suggested that combining various…
Abstract Number: 349 • 2013 ACR/ARHP Annual Meeting
Serum CTX-I Predicts Systemic Bone Loss At The Hip Over 1 Year In Patients With Early Psoriatic Arthritis
Agnes Szentpetery¹, Mark Kilbane², Myra P. O'Keane², Muhammad Haroon³, Phil Gallagher⁴, Susan van der Kamp⁵, Malachi McMenna⁶ and Oliver FitzGerald³, ¹Rheumatology, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland, ²Metabolism Laboratory, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland, ³Department of Rheumatology, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland, ⁴Rheumatology, St. Vincent's University Hospital, Dublin, Ireland, ⁵DXA Unit, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland, ⁶Department of Endocrinology & Metabolic Bone Disease, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland
Background/Purpose: There is a growing interest in bone and cartilage biomarkers that could be used predicting and assessing changes in structural damage in inflammatory arthritis.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].